Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Brenner

Showing results (101-110 of 126) with videos related to

Pageof 13
Sort By:
Nature Aging|June 4, 2024
Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositisSven Wischnewski, Thomas Thäwel, Chiseko Ikenaga, et al.
European Journal of Neurology|April 4, 2025
Population-Based Versus Hospital-Based Data in Amyotrophic Lateral Sclerosis-A Factor to Consider?Johannes Dorst, Jens Dreyhaupt, Deborah Wernecke, et al.
Brain Communications|April 3, 2023
Clinical and genetic features of amyotrophic lateral sclerosis patients with <i>C9orf72</i> mutationsMaximilian Wiesenfarth, Kornelia Günther, Kathrin Müller, et al.
Annals of Neurology|August 23, 2024
Population-Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral SclerosisSimon Witzel, André Huss, Gabriele Nagel, et al.
Journal of Neurology|March 8, 2025
Correction: Clinical characterization of common pathogenic variants of SOD1-ALS in GermanyMaximilian Wiesenfarth, Yalda Forouhideh-Wiesenfarth, Zeynep Elmas, et al.
Journal of Neurology|August 14, 2024
Clinical characterization of common pathogenic variants of SOD1-ALS in GermanyMaximilian Wiesenfarth, Yalda Forouhideh-Wiesenfarth, Zeynep Elmas, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 28, 2026
RIG-I Mediated Neuron-Specific IFN Type 1 Signaling in FUS-ALS Induces Neurodegeneration and Offers New Biomarker-Driven Individualized Treatment Options for (FUS-)ALSMarcel Naumann, Theresa M Wierschin, Stefanie Kretschmer, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 14, 2018
Comprehensive analysis of the mutation spectrum in 301 German ALS familiesKathrin Müller, David Brenner, Patrick Weydt, et al.
Brain Communications|November 3, 2025
Deep clinical, genetic, and serum biomarker profiling indicates glial and neuronal pathology in primary brain calcificationJanine Schwahn, Sophie Hebestreit, Olivia Kosche, et al.
The Journal of Experimental Medicine|March 22, 2024
A TBK1 variant causes autophagolysosomal and motoneuron pathology without neuroinflammation in miceDavid Brenner, Kirsten Sieverding, Jahnavi Srinidhi, et al.
Pageof 13

Showing results (101-110 of 126) with videos related to

Sort By:
Pageof 13
Nature Aging|June 4, 2024
Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositisSven Wischnewski, Thomas Thäwel, Chiseko Ikenaga, et al.
European Journal of Neurology|April 4, 2025
Population-Based Versus Hospital-Based Data in Amyotrophic Lateral Sclerosis-A Factor to Consider?Johannes Dorst, Jens Dreyhaupt, Deborah Wernecke, et al.
Brain Communications|April 3, 2023
Clinical and genetic features of amyotrophic lateral sclerosis patients with <i>C9orf72</i> mutationsMaximilian Wiesenfarth, Kornelia Günther, Kathrin Müller, et al.
Annals of Neurology|August 23, 2024
Population-Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral SclerosisSimon Witzel, André Huss, Gabriele Nagel, et al.
Journal of Neurology|March 8, 2025
Correction: Clinical characterization of common pathogenic variants of SOD1-ALS in GermanyMaximilian Wiesenfarth, Yalda Forouhideh-Wiesenfarth, Zeynep Elmas, et al.
Journal of Neurology|August 14, 2024
Clinical characterization of common pathogenic variants of SOD1-ALS in GermanyMaximilian Wiesenfarth, Yalda Forouhideh-Wiesenfarth, Zeynep Elmas, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 28, 2026
RIG-I Mediated Neuron-Specific IFN Type 1 Signaling in FUS-ALS Induces Neurodegeneration and Offers New Biomarker-Driven Individualized Treatment Options for (FUS-)ALSMarcel Naumann, Theresa M Wierschin, Stefanie Kretschmer, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 14, 2018
Comprehensive analysis of the mutation spectrum in 301 German ALS familiesKathrin Müller, David Brenner, Patrick Weydt, et al.
Brain Communications|November 3, 2025
Deep clinical, genetic, and serum biomarker profiling indicates glial and neuronal pathology in primary brain calcificationJanine Schwahn, Sophie Hebestreit, Olivia Kosche, et al.
The Journal of Experimental Medicine|March 22, 2024
A TBK1 variant causes autophagolysosomal and motoneuron pathology without neuroinflammation in miceDavid Brenner, Kirsten Sieverding, Jahnavi Srinidhi, et al.
Pageof 13